Expert opinion on expanding anti-HBV treatment for chronic hepatitis B.
10.3760/cma.j.cn501113-20220209-00060
- VernacularTitle:扩大慢性乙型肝炎抗病毒治疗的专家意见
- Collective Name:Chinese Society of Hepatology, Chinese Medical Association
- Publication Type:Journal Article
- Keywords:
Chronic hepatitis B;
Indication;
Treatment
- MeSH:
Alanine Transaminase;
DNA, Viral;
Expert Testimony;
Hepatitis B Surface Antigens;
Hepatitis B, Chronic/drug therapy*;
Humans
- From:
Chinese Journal of Hepatology
2022;30(2):131-136
- CountryChina
- Language:Chinese
-
Abstract:
To meet the unmet medical needs and better reflect the new clinical evidence of chronic hepatitis B management, Chinese Society of Hepatology developed expert consensus on expanding diagnosis and treatment in China. The recommendations include to expand HBsAg screening in the population and HBV DNA detection by sensitive quantitative real-time PCR (qPCR), decrease the alanine aminotransferase (ALT) threshold for treatment of chronic hepatitis B, and promptly start antiviral therapy in the patients who are at risk of disease progression, and appropriately manage the patients with low level viremia.
